A citation-based method for searching scientific literature

C David Mazer, Gregory M T Hare, Philip W Connelly, Richard E Gilbert, Nadine Shehata, Adrian Quan, Hwee Teoh, Lawrence A Leiter, Bernard Zinman, Peter Jüni, Fei Zuo, Nikhil Mistry, Kevin E Thorpe, Ronald M Goldenberg, Andrew T Yan, Kim A Connelly, Subodh Verma. Circulation 2020
Times Cited: 60







List of co-cited articles
569 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
61

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
56

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
48

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
279
48

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
45

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
856
40

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
36

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
399
31

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett,[...]. Circulation 2019
114
30

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
Subodh Verma, Sonia Rawat, Kim L Ho, Cory S Wagg, Liyan Zhang, Hwee Teoh, John E Dyck, Golam M Uddin, Gavin Y Oudit, Eric Mayoux,[...]. JACC Basic Transl Sci 2018
115
23

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Karen M Hallow, Gabriel Helmlinger, Peter J Greasley, John J V McMurray, David W Boulton. Diabetes Obes Metab 2018
138
23


Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
23

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
162
20

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
383
20

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
188
18


Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
678
18

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
JingWei Li, Mark Woodward, Vlado Perkovic, Gemma A Figtree, Hiddo J L Heerspink, Kenneth W Mahaffey, Dick de Zeeuw, Frank Vercruysse, Wayne Shaw, David R Matthews,[...]. JACC Heart Fail 2020
26
42

Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.
Husam Ghanim, Sanaa Abuaysheh, Jeanne Hejna, Kelly Green, Manav Batra, Antione Makdissi, Ajay Chaudhuri, Paresh Dandona. J Clin Endocrinol Metab 2020
16
68

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
169
18

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
204
18

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Yevgeniy Khariton, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin,[...]. Circulation 2019
93
15

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
224
15

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Carlos G Santos-Gallego, Juan Antonio Requena-Ibanez, Rodolfo San Antonio, Kiyotake Ishikawa, Shin Watanabe, Belen Picatoste, Eduardo Flores, Alvaro Garcia-Ropero, Javier Sanz, Roger J Hajjar,[...]. J Am Coll Cardiol 2019
127
15



SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
David A Hess, Daniella C Terenzi, Justin Z Trac, Adrian Quan, Tamique Mason, Mohammed Al-Omran, Deepak L Bhatt, Natasha Dhingra, Ori D Rotstein, Lawrence A Leiter,[...]. Cell Metab 2019
27
29

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.
Nikole J Byrne, Nirmal Parajuli, Jody L Levasseur, Jamie Boisvenue, Donna L Beker, Grant Masson, Paul W M Fedak, Subodh Verma, Jason R B Dyck. JACC Basic Transl Sci 2017
70
13

Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
Alana Aragón-Herrera, Sandra Feijóo-Bandín, Manuel Otero Santiago, Luis Barral, Manuel Campos-Toimil, José Gil-Longo, Thiago M Costa Pereira, Tomás García-Caballero, Santiago Rodríguez-Segade, Javier Rodríguez,[...]. Biochem Pharmacol 2019
28
28

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
Sarah J Mancini, Daria Boyd, Omar J Katwan, Anastasiya Strembitska, Tarek A Almabrouk, Simon Kennedy, Timothy M Palmer, Ian P Salt. Sci Rep 2018
65
13

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Volker Vallon, Maria Gerasimova, Michael A Rose, Takahiro Masuda, Joseph Satriano, Eric Mayoux, Hermann Koepsell, Scott C Thomson, Timo Rieg. Am J Physiol Renal Physiol 2014
244
13

SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection.
Lakshini Y Herat, Aaron L Magno, Caroline Rudnicka, Jana Hricova, Revathy Carnagarin, Natalie C Ward, Angelique Arcambal, Marcio G Kiuchi, Geoff A Head, Markus P Schlaich,[...]. JACC Basic Transl Sci 2020
33
24

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Erik J M van Bommel, Marcel H A Muskiet, Michaël J B van Baar, Lennart Tonneijck, Mark M Smits, Anna L Emanuel, Andrea Bozovic, A H Jan Danser, Frank Geurts, Ewout J Hoorn,[...]. Kidney Int 2020
72
13

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Yumo Zhao, Lubin Xu, Dongli Tian, Peng Xia, Hua Zheng, Li Wang, Limeng Chen. Diabetes Obes Metab 2018
89
13

Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
Claire C J Dekkers, C David Sjöström, Peter J Greasley, Valerie Cain, David W Boulton, Hiddo J L Heerspink. Diabetes Obes Metab 2019
22
31

Treatment of anemia with darbepoetin alfa in systolic heart failure.
Karl Swedberg, James B Young, Inder S Anand, Sunfa Cheng, Akshay S Desai, Rafael Diaz, Aldo P Maggioni, John J V McMurray, Christopher O'Connor, Marc A Pfeffer,[...]. N Engl J Med 2013
281
11

Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Roni Nielsen, Niels Møller, Lars C Gormsen, Lars Poulsen Tolbod, Nils Henrik Hansson, Jens Sorensen, Hendrik Johannes Harms, Jørgen Frøkiær, Hans Eiskjaer, Nichlas Riise Jespersen,[...]. Circulation 2019
74
11

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
242
11

Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Elisabetta Barsotti, Aldo Clerico, Elza Muscelli. Diabetes Care 2017
67
11

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
535
11


2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
693
11


Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, Christopher P Cannon, Bruce Neal, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris,[...]. Circulation 2019
89
11

Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
Matthew Griffin, Veena S Rao, Juan Ivey-Miranda, James Fleming, Devin Mahoney, Christopher Maulion, Nisha Suda, Krishmita Siwakoti, Tariq Ahmad, Daniel Jacoby,[...]. Circulation 2020
53
13

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
256
11

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
S Sha, D Polidori, T Heise, J Natarajan, K Farrell, S-S Wang, D Sica, P Rothenberg, L Plum-Mörschel. Diabetes Obes Metab 2014
133
10

Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.
Hao Zhou, Shuyi Wang, Pingjun Zhu, Shunying Hu, Yundai Chen, Jun Ren. Redox Biol 2018
173
10

The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.
Simon A Hawley, Rebecca J Ford, Brennan K Smith, Graeme J Gowans, Sarah J Mancini, Ryan D Pitt, Emily A Day, Ian P Salt, Gregory R Steinberg, D Grahame Hardie. Diabetes 2016
136
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.